More tools:Markets·Screener·Research Chat

Amgen Inc (AMGN) Financial Statements

Amgen Inc
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S5NNL6
XNAS · usd
355.25▼ 5.20 (-1.44%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)$37.2B
Net Income (TTM)$7.8B
EBITDA
Diluted EPS (TTM)
EBITDA Margin41.5%
Net Debt
Trading Information
Previous Close360.45
Day's Range354.71 – 358.86
52-Week Range269.77 – 391.34
Volume1.53M
Avg Volume2.76M
Share Statistics
Shares Outstanding539.7M
Employees31.5K
ExchangeXNAS
Listed1983-06-17

Key questions about Amgen Inc (AMGN)

What is Amgen Inc's Market Cap?
Amgen Inc's Market Cap is $191.7B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Enterprise Value?
Amgen Inc's Enterprise Value is $240.0B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Trailing P/E?
Amgen Inc's Trailing P/E is 24.6×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Price / Sales?
Amgen Inc's Price / Sales is 5.2×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's EV / Revenue?
Amgen Inc's EV / Revenue is 6.4×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's EV / EBITDA?
Amgen Inc's EV / EBITDA is 15.5×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Revenue (TTM)?
Amgen Inc's Revenue (TTM) is $37.2B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Net Income (TTM)?
Amgen Inc's Net Income (TTM) is $7.8B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's EBITDA?
Amgen Inc's EBITDA is $15.5B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Diluted EPS (TTM)?
Amgen Inc's Diluted EPS (TTM) is 14.45, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Revenues:
Product sales
Other revenues
Total revenues
YoY growth+5.8%+8.6%+12.4%+9.4%
Operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Other———
Total operating expenses
% of revenue69.1%72.4%73.6%71.1%
Income (loss) from operations
% of revenue30.9%27.6%26.4%28.9%
Other income (expense):
Interest expense, net
Other income, net
Income (loss) before income taxes———
Income tax expense (benefit)
Net income (loss)
% of revenue21.1%13.5%33.7%15.6%
Earnings per share:
Basic
Diluted
Weighted-average shares used in calculation of earnings per share:
Basic
Diluted